New HIV infections worldwide occur every 25 seconds and a vaccine is the only long-term solution to this epidemic. A new attenuated strain of Listeria monocytogenes is a vector with potential for use as an oral vaccine against the disease. In Project 1 of this application several recombinants of attenuated Listeria that individually express various foreign genes will be generated by standard cloning methods: the flourochrome DsRed, for use in mouse experiments, SIV gag and nef, 89.6 tat, and the envelope genes of SHIV 89.6P and SHIV 1157ip for use in trials in juvenile and adult rhesus monkeys, and new recombinants of the attenuated Listeria that express a consensus-type clade B env sequence, JRFL, and a clade B'C env sequence from Beijing for potential use in future human studies. This core project is designed to (1) generate amounts of these recombinant bacteria commensurate with the needs of the various projects using them and (2) to assure the authenticity of the organisms by characterizing the preparations with respect to their genetic correctness, their lack of reversion to wild-type, their safety and immunogenicity in mice, and their expression of the desired heterologous proteins. We will also explore the ability of a synthetic medium to be used for the growth of the organisms so as to eliminate from future preparations, if possible, the complex, poorly characterized molecules that currently are used in their growth medium.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
3P01AI054558-05S1
Application #
7952753
Study Section
Special Emphasis Panel (ZAI1-HSD-A (J1))
Project Start
2009-08-11
Project End
2010-01-31
Budget Start
2009-08-11
Budget End
2010-01-31
Support Year
5
Fiscal Year
2009
Total Cost
$89,044
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
059709394
City
Boston
State
MA
Country
United States
Zip Code
02115
Sciaranghella, Gaia; Lakhashe, Samir K; Ayash-Rashkovsky, Mila et al. (2011) A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly. Vaccine 29:476-86
Lakhashe, Samir K; Velu, Vijayakumar; Sciaranghella, Gaia et al. (2011) Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29:5611-22
Lakhashe, Samir K; Silvestri, Guido; Ruprecht, Ruth M (2011) No acquisition: a new ambition for HIV vaccine development? Curr Opin Virol 1:246-53
Li, Zhongxia; Zhang, Manxin; Zhou, Chenghui et al. (2008) Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 180:2504-13
Lenz, Laurel L; Huang, William A; Zhou, Chenghui et al. (2008) Stable integration vector for nutrient broth-based selection of attenuated Listeria monocytogenes strains with recombinant antigen expression. Clin Vaccine Immunol 15:1414-9
Jiang, Shisong; Rasmussen, Robert A; Nolan, Katrina M et al. (2007) Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 25:7470-9